4. Antiviral therapies: Interferon -alpha (adult: 5 million units or equivalent dose in 2 mL of sterile water for mJection delivered with a nebulizer, twice daily (bid)), Lopinavir/Ritonavir (adult: 200 mg/50 mg/unit, 2 units bid for a treatment course of not more than]O days), Ribavirin (recommended in combination with interferon or Lopinavir/Ritonavir, adult: 500 mg IV, bid or three times daily (tid) for a treatment course of not more than IO days), chloroquine phosphate (adult: 500 mg bid for not more than IO days) , Arbidol (adult: 200 mg tid for a treatment course of not more than IO days) could be the antiviral treatment options for COVID-19. Attention should be paid to adverse reactions (such as diarrhea, nausea , vomiting, and hepatic impairment) associated with Lopinavir/Ritonavir as well as their interactions with other drugs. The efficacy of these drugs for COVID-19 still need to be further evaluated and confirmed in clinical use. Concomitant use of 3 or more antiviral drugs is not recommended. And corresponding medication should be discontinued if intolerable toxicities occur.
4. Antiviral therapies: Interferon -alpha (adult: 5 million units or equivalent dose in 2 mL of sterile water for injection delivered with a nebulizer, twice daily [bid]), Lopinavir/ Ritonavir (adult: 200 mg/50 mg/unit, 2 units bid for a treatment course of not more than IO days), Ribavirin (recommended in combination with interferon or Lopinavir/ Ritonavir, adult: 500 mg IV, bid or three times daily [tid] for a treatment course of not more than I 0 days), chloroquine phosphate (adult 18-65 years of age: 500 mg bid for 7 days for those weighing more than 50 kg; 500 mg bid on Day I and Day 2, 500 mg once daily [qd] from Day 3 to Day 7 for those weighing Jess than 50 kg), and Arbidol (adul t: 200 mg tid for a treatment course of not more than 10 days) could be the antiviral treatment options for COVID-19. These drugs should be used with attention id to the adverse reactions and contraindications associated with the above-mention ed medications (e.g., chloroquine is contraindicated in patients with heart disease), as well as their interactions with other drugs. The efficacy of these drugs for COVID-19 still need to be further evaluated and confirmed in clinical use. Concomitant use of 3 or more antiviral drugs is not recommended. And corresponding medication should be discontinued if intolerable toxicities occur. For the treatment of iregnant women' some concerns should be taken into considerations, including gestation week, selection of drugs with minimal fetal effects if possible, and whether to terminate the iregnancy before treatment; and the informed consent should be obtained before treatment
| Patient Type | Recomended Regimen | Dosage and Administration |
| Adults |
|
Adult: 200 mg tid for a treatinent course of not more than 10 days |
| Children | Guidance for Antiviral Treatment of COVID-19 in Special Populations | 1-2 years of age: 10 mg/kg/day 2-6 years of age: 0.05 g tid 6-12 years of age: 0.1 g tid |
| Elderly | Guidance for Antiviral Treatment of COVID-19 in Special Populations | Russian studies show that the use of Arbidol can reduce the incidence of nosocomial pneumonia in people over 65 years of age compared with those not treated with Arbidol. Therefore, Arbidol can be used in elderly patients for the treatment of COVID-19. |
H ap y 111e 11UR co c n ,o p o ll bl U ILIIY II II OU CU Cll/ l!,ll bl : peiJKO - (U/J/ep 211<"teCKUe pe a Kl /11/J. Ecn 11 mo 6b 1e H3 yKa33HHbJX e HHCTPYK111111 no6o Hb1x '.)cjlcpeKToe yc yr y6n JOTc , 11n11 Bb l 3aMeT11n11 mo6b 1e ,11pyr11e no6o HbJe '.)cpcpeKTbl, He yKa3aHHbJe BHHCTPYKl11111, coo 6 )UHTe06 '.)TOM ep a y. B m tH H lf C Ha CROC.OOHOCTb yn p a wt HTb Tp a H cn op TH bl M lf cp CJICTB8 M lf H M CX8 H lf 3M 8 M lf He npo en eT ueHTPanbHOH HeiipoTPonHoii aKTHBHOCTl1 11 MO)l(eT npHMeH TbC e Me,11111111HcK011 npaKT11Ke y m111 pa1n11 Hbl X npocpecCHH, B T. . TPe6yiom11x nOBbtWeHHOro BHl1MaHH 11 KOOp,!IHHaUHH ,!1811)1(eHHl1 (eo,1111Ten11 i-paHcnopTa, onepaTOpbt 11 T.,11. )
